CA3073392C - Cytocidal agent - Google Patents
Cytocidal agent Download PDFInfo
- Publication number
- CA3073392C CA3073392C CA3073392A CA3073392A CA3073392C CA 3073392 C CA3073392 C CA 3073392C CA 3073392 A CA3073392 A CA 3073392A CA 3073392 A CA3073392 A CA 3073392A CA 3073392 C CA3073392 C CA 3073392C
- Authority
- CA
- Canada
- Prior art keywords
- peptide
- cngb3
- cell
- amino acids
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Environmental Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017-161556 | 2017-08-24 | ||
| JP2017161556A JP6613499B2 (ja) | 2017-08-24 | 2017-08-24 | 細胞殺傷剤 |
| PCT/JP2018/031136 WO2019039540A1 (ja) | 2017-08-24 | 2018-08-23 | 細胞殺傷剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3073392A1 CA3073392A1 (en) | 2019-02-28 |
| CA3073392C true CA3073392C (en) | 2023-02-21 |
Family
ID=65438932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3073392A Active CA3073392C (en) | 2017-08-24 | 2018-08-23 | Cytocidal agent |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11357819B2 (enExample) |
| EP (1) | EP3738601A4 (enExample) |
| JP (1) | JP6613499B2 (enExample) |
| KR (1) | KR102427844B1 (enExample) |
| CN (1) | CN111065403B (enExample) |
| AU (1) | AU2018322305B2 (enExample) |
| CA (1) | CA3073392C (enExample) |
| SG (1) | SG11202001484QA (enExample) |
| WO (1) | WO2019039540A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6613499B2 (ja) | 2017-08-24 | 2019-12-04 | 学校法人藤田学園 | 細胞殺傷剤 |
| WO2019138944A1 (ja) | 2018-01-09 | 2019-07-18 | 学校法人藤田学園 | 細胞殺傷剤 |
| JP2024517518A (ja) * | 2021-05-07 | 2024-04-23 | ツインピグ バイオラブ インコーポレイテッド | マクロファージを標的とするペプチド、ならびにそのコンジュゲート、組成物、および使用 |
| CN115725968A (zh) * | 2022-11-18 | 2023-03-03 | 东莞宜安科技股份有限公司 | 一种生物医用钛合金表面的复合涂层及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| CA2634934A1 (en) * | 2005-12-23 | 2007-07-05 | The Burnham Institute For Medical Research | Endometriosis cell targeting peptide and uses thereof |
| EP2414389A1 (en) * | 2009-04-01 | 2012-02-08 | Schmidt-Wolf, Ingo | Tumor targeting peptides, therapeutic and diagnostic compositions comprising the peptides |
| WO2011027312A1 (en) * | 2009-09-03 | 2011-03-10 | Koninklijke Philips Electronics N.V. | NOVEL TUMOR MARKERS SELECTED FROM A GROUP OF cAMP-REGULATORY PATHWAY MEMBERS |
| JP6184101B2 (ja) * | 2009-12-23 | 2017-08-23 | サンフォード−バーナム メディカル リサーチ インスティテュート | アネキシン１結合化合物に関する方法および組成物 |
| EP3238782A3 (en) * | 2010-04-06 | 2018-01-03 | ExoCyte Therapeutics Pte, LTD | Methods of treating cancer |
| WO2014028861A1 (en) * | 2012-08-17 | 2014-02-20 | Apellis Pharmaceuticals, Inc. | Detection of high risk drusen |
| US9783576B2 (en) * | 2013-06-11 | 2017-10-10 | Sanford-Burnham Medical Research Institute | Compositions and methods for targeted endometriosis treatment |
| US10338068B2 (en) * | 2013-07-08 | 2019-07-02 | The Trustees Of Columbia University In The City Of New York | Selection of biological objects |
| JPWO2015041019A1 (ja) * | 2013-09-18 | 2017-03-02 | 国立大学法人京都大学 | 子宮内膜症様細胞の作製方法および子宮内膜症モデル動物 |
| AU2015366284B2 (en) | 2014-12-19 | 2021-07-22 | Ablynx N.V. | Cysteine linked nanobody dimers |
| RU2571551C1 (ru) | 2015-04-16 | 2015-12-20 | Закрытое акционерное общество "ПЕПТЕК" | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором |
| JP2017161556A (ja) | 2017-06-27 | 2017-09-14 | パイオニア株式会社 | 位置認識装置、制御方法、プログラム、及び記憶媒体 |
| JP6613499B2 (ja) | 2017-08-24 | 2019-12-04 | 学校法人藤田学園 | 細胞殺傷剤 |
-
2017
- 2017-08-24 JP JP2017161556A patent/JP6613499B2/ja active Active
-
2018
- 2018-08-23 US US16/640,248 patent/US11357819B2/en active Active
- 2018-08-23 SG SG11202001484QA patent/SG11202001484QA/en unknown
- 2018-08-23 AU AU2018322305A patent/AU2018322305B2/en active Active
- 2018-08-23 KR KR1020207004917A patent/KR102427844B1/ko active Active
- 2018-08-23 CA CA3073392A patent/CA3073392C/en active Active
- 2018-08-23 CN CN201880054701.XA patent/CN111065403B/zh active Active
- 2018-08-23 WO PCT/JP2018/031136 patent/WO2019039540A1/ja not_active Ceased
- 2018-08-23 EP EP18848077.6A patent/EP3738601A4/en active Pending
-
2022
- 2022-05-10 US US17/740,864 patent/US20220280596A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN111065403B (zh) | 2023-09-26 |
| AU2018322305B2 (en) | 2021-05-20 |
| CA3073392A1 (en) | 2019-02-28 |
| WO2019039540A1 (ja) | 2019-02-28 |
| JP2019038772A (ja) | 2019-03-14 |
| KR20200031670A (ko) | 2020-03-24 |
| JP6613499B2 (ja) | 2019-12-04 |
| CN111065403A (zh) | 2020-04-24 |
| SG11202001484QA (en) | 2020-03-30 |
| KR102427844B1 (ko) | 2022-07-29 |
| US20200289608A1 (en) | 2020-09-17 |
| EP3738601A4 (en) | 2021-06-16 |
| EP3738601A1 (en) | 2020-11-18 |
| AU2018322305A1 (en) | 2020-03-05 |
| US20220280596A1 (en) | 2022-09-08 |
| US11357819B2 (en) | 2022-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220280596A1 (en) | Cytocidal agent | |
| Djiogue et al. | Insulin resistance and cancer: the role of insulin and IGFs | |
| Hsu et al. | The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling | |
| Kim et al. | Tumor-suppressive effect of a telomerase-derived peptide by inhibiting hypoxia-induced HIF-1α-VEGF signaling axis | |
| ES2844874T3 (es) | Complejo de proteína de leche y ácido graso | |
| Leskov et al. | CRM1 protein-mediated regulation of nuclear clusterin (nCLU), an ionizing radiation-stimulated, Bax-dependent pro-death factor | |
| Yang et al. | Upregulation of Parkinson's disease-associated protein alpha-synuclein suppresses tumorigenesis via interaction with mGluR5 and gamma-synuclein in liver cancer | |
| Kim et al. | Clusterin interaction with Bcl-xL is associated with seizure-induced neuronal death | |
| KR101401891B1 (ko) | 테모졸로미드 및 발프로산을 함께 이용하는 항암적 용도 | |
| US9581598B2 (en) | Diagnosis and treatment of brain tumor | |
| CA3087744C (en) | CYTOCIDAL AGENT | |
| HK40023962A (zh) | 细胞杀伤剂 | |
| Wang et al. | Construction of human LRIG1-TAT fusions and TAT-mediated LRIG1 protein delivery | |
| Yuan et al. | Targeted intracellular delivery of BH3 mimetic peptide inhibits BCL-2 activity and prevents breast cancer development | |
| Midavaine et al. | CCR2 silencing in sensory neurons blocks bone cancer progression | |
| Jin et al. | Epithelial ovarian cancer: feasibility of image-guided intratumoral radiofrequency hyperthermia-enhanced direct gene therapy | |
| Zhu et al. | Pomolic acid alleviates CCl4‑induced liver fibrosis in mice by suppressing β-arrestin 2-mediated M2 macrophage polarization | |
| Martinez Andrade | The targeted delivery of G3 peptide drug conjugates in prostate cancer | |
| Zhou | Selective knockdown of misfolded SOD1 as a therapy for amyotrophic lateral sclerosis | |
| TWI602572B (zh) | 抗菌胜肽tp4治療癌症之用途 | |
| Chiou | Redefining the Role of H-Ferritin in the Brain | |
| Tsai | Cell Surface Translocation Mechanism of Stress-Inducible GRP78 in Human Cancer | |
| JP2020030120A (ja) | 疾患発症可能性の評価方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200219 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240807 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240807 |